documents incorporated reference incorporated scheringplough corporation parts ii iv annual report shareholders scheringplough corporation proxy part iii statement annual meeting shareholders april part item business terms scheringplough company used herein refer scheringplough corporation subsidiaries except otherwise indicated context scheringplough corporation holding company incorporated trademarks indicated capital letters property licensed promoted distributed scheringplough corporation subsidiaries related companies subsidiaries scheringplough corporation engaged discovery development manufacturing marketing pharmaceutical products worldwide discovery development efforts target field human health however application field animal health result efforts company views animal health applications means maximize return investments discovery development company operates primarily prescription pharmaceutical marketplace however appropriate company sought regulatory approval switch prescription products thecounter otc status means extending product 's life cycle way otc marketplace yet another means maximizing return investments discovery development prescription products include claritin claritind nasonex proventil vancenase vanceril allergyrespiratory eulexin intron pegintron rebetron combination therapy containing rebetol ribavirin capsules intron injection remicade temodar antiinfective anticancer diprolene diprosone elocon lotrisone dermatologicals imdur integrilin kdur nitrodur cardiovasculars andcelestone subutex pharmaceuticals animal health products include cepravin nuflor antimicrobials banamine nonsteroidal antiinflammatory ralgro growth promotant implant otomax otic product broad range vaccines many species parasiticides sutures bandages nutritional products foot care otc sun care products include clear away wart remover dr scholl 's foot care products lotrimin af tinactin antifungals ointment afrin nasal decongestant chlortrimeton antihistamine coricidin drixoral cold decongestant products correctol laxative bain de soleil coppertone solarcaine sun care products net sales major product therapeutic category dollars millions years ended december percent change allergy respiratory claritin nasonex proventil vancenase vanceril allergy respiratory antiinfective anticancer intron arebetron eulexin temodar nm remicade nm antiinfective anticancer cardiovasculars kdur integrilin nm nitrodur imdur cardiovasculars dermatologicals lotrisone elocon dermatologicals pharmaceuticals worldwide pharmaceuticals animal health foot care otc sun care consolidated net sales nm meaningful certain amounts reclassified selling general administrative expense net sales comply eitf issue accounting certain sales incentives segment information set forth notes consolidated financial statements company 's annual report shareholders incorporated herein reference prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distributing samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers foot care otc sun care products sold wholesale retail drug food chain mass merchandiser outletsand promoted directly consumer television radio internet print advertising media company 's subsidiaries licensed rights number patents patent applications united states abroad patents patent applications relating company 's significant products including without limitation claritin family products intron rebetron combination therapy containing rebetol capsules intron injection pegintron material importance company certain claritin loratadine related patents expire next several years specifically loratadine compound patent claritin united states expires compound patent desloratadine active metabolite loratadine expires patents subject litigation described item legal proceedings worldwide company 's products sold trademarks trademarks considered aggregate material importance business protected registration common law united states markets products sold raw materials essential company available adequate quantities number potential suppliers energy expected available company sufficient quantities meet operating requirements seasonal patterns pronounced effect consolidated operations company pharmaceutical industry highly competitive includes large companies substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used company products include research development new improved products high product quality varied dosage forms strengths switching prescription products nonprescription status united states many company 's products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products become longer protected patents data exclusivity arrangements fda percent percent percent respectively consolidated net sales made mckesson hboc inc major pharmaceutical health care products distributor substantially sales united states foreign operations foreign activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition company represented markets licensees distribution arrangements approximately employees outside united states foreign operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations restrictive governmental actions also fluctuations foreign currency exchange rates impact company 's consolidated financial results additional information foreign operations see management 's discussion analysis operations financial condition segment information company 's annual report shareholders incorporated herein reference research development company 's research activities primarily aimed discovering developing new enhanced prescription products medical commercial significance company sponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales approximately percent consolidated net sales company 's research activities concentrated therapeutic areas allergic inflammatory disorders infectious diseases oncology cardiovascular diseases central nervous system disorders company also substantial efforts directed toward biotechnology gene therapy immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale among products awaiting fda approval march last day prior printing report clarinex tablets desloratadine asmanex mometasone furoate allergyrespiratory rebetol capsules pegintron rebetol combination therapy antiinfective government regulation pharmaceutical companies subject extensive regulation number national state local agencies particular importance united states food drug administration fda jurisdiction company 's businesses administers requirements covering testing approval safety effectiveness manufacturing labeling marketing company 's products extent fda requirements andor reviews affects amount resources necessary develop new products bring market united states fda also regulates whether prescription drugs switched prescription overthecounter otc status thatregard company recently informed may date thereafter fda hold joint advisory committee meeting fda 's pulmonary allergy drug products division otc division consider citizens ' petition filed fda requesting otc switch loratadine two antihistamines marketed companies ongoing basis fda regulates facilities procedures used manufacture pharmaceutical products united states sale united states products made facilities must manufactured accordance good manufacturing practices gmps established fda fda periodically inspects company 's facilities procedures assure compliance fda conducting inspections company 's manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current gmps primarily relating production processes controls procedures continuing evaluate issues raised information provided company connection fda inspections company taken extensive measures intended enhance manufacturing processes controls company notes fda 's inspection reports internal reviews indicate improvements required fda advised company gmp deficiencies cited facility inspection reports must resolved prior granting approval company 's pending new drug application nda clarinex desloratadine tablets failure comply government regulations result delays release products delays approvals new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions company 's activities outside united states also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing company 's products regulatory requirements vary country country whether fda approval approval european medicines evaluation agency obtained product approval product comparable regulatory authorities countries outside united states european union case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required united states approval one country assure product approved another country international markets company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods cost control recent years various legislative proposals offered congress state legislatures would effect major changes affected health care systems one change could material company possible addition outpatient prescription drug benefit medicare states passed legislation federal state legislative administrative proposals possible could include price patient reimbursement constraints medicines mandated discounts expansion existing governmental programs new patient populations restrictions access certain products similar issues also arisen many countries outside united states possible predict outcome initiatives effect operations cash flows reasonably estimated company also subject jurisdiction various regulatory enforcement departments agencies federal trade commission ftc department justice department health human services united states company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies environment date compliance federal state local environmental protection laws materially adverse effect company company made continue make necessary expenditures environmental protection worldwide capital expenditures included approximately million environmental control purposes anticipated continued compliance environmental regulations significantly affect company 's financial statements competitive position additional information environmental matters see legal environmental matters notes consolidated financial statements company 's annual report shareholders incorporated herein reference employees approximately people employed company december cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made timetotime company may contain socalled forwardlooking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects believes anticipates words similar meaning one also identify fact relate strictly historical current facts statements likely address company 's growth strategy financial results regulatory issues status product approvals development programs litigation investigations may also relate expected impact thecompany 's firstquarter fullyear sales earnings manufacturing process control issues described herein company 's efforts going forward resolve gmp issues identified fda company 's internal reviews certain company 's manufacturing facilities remedies fda may seek respect issues expected need cost additional remedial actions company may take pendency company 's nda clarinex remains subject fda approval one must carefully consider statement understand many factors could cause actual results differ company 's forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement although possible predict identify factors may include following significant portion net sales made major pharmaceutical health care products distributors major retail chains united states consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors competitive factors including technological advances attained competitors patents granted competitors new products competitors coming market new indications competitive products generic competition company 's products mature patents expire products increased pricing pressure united states abroad managed care buyers institutions government agencies united states among developments consolidation among customers may increase pricing pressures may result various customers greater influence prescription decisions formulary decisions policies government laws regulations changes laws regulations affecting domestic international operations enforcement thereof including among laws regulations resulting healthcare reform initiatives united states state federal level countries well laws regulations relating trade antitrust monetary fiscal policies taxes price controls possible nationalization patent positions highly uncertain patent disputes unusual adverse result patent dispute preclude commercialization products negatively impact sales existing products result injunctive relief payment financial remedies uncertainties fda approval process regulatory approval processes nonus countries including without limitation delays approval new products failure meet gmps established fda governmental authorities result delays release products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions resolution manufacturing issues fda discussed report well potential impact issues company 's firstquarter fullyear sales earnings subject substantial risks uncertainties risks uncertainties including timing scope duration resolution manufacturing issues depend ability company assure fda quality reliability manufacturing systems controls extent remedial prospective obligations undertaken company difficulties product development pharmaceutical product development highly uncertain products appear promising development may fail reach market numerous reasons may found ineffective harmful side effects clinical preclinical testing may fail receive necessary regulatory approvals may turn economically feasible manufacturing costs factors may precluded commercialization proprietary rights others efficacy safety concerns respect marketed products whether scientifically justified leading recalls withdrawals declining sales major products claritin intron arebetron combination therapy rebetol capsules accounted material portion company 's revenues major product claritin intron arebetron combination therapy rebetol become subject problem loss patent protection previously unknown side effects new effective treatment introduced impact revenues could significant failure company foresee correct systems commercial arrangements address new european currency euro legal factors including product liability claims litigation government investigations patent disputes competitors environmental concerns could preclude commercialization products negatively affect profitability existing products economic factors company control including changes inflation interest rates foreign currency exchange rateschanges tax laws including changes related taxation foreign earnings changes accounting standards promulgated american institute certified public accountants financial accounting standards board securities exchange commission adverse company item properties company 's corporate headquarters located kenilworth new jersey principal manufacturing facilities located kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina australia belgium canada colombia france germany ireland italy japan mexico singapore spain company 's principal research facilities located kenilworth union new jersey palo alto san diego california elkhorn nebraska major portion properties owned company properties well maintained adequately insured good operating condition company 's manufacturing facilities capacities considered appropriate meet company 's needs item legal proceedings subsidiaries company defendants lawsuits involving approximately plaintiffs arising use synthetic estrogens mothers plaintiffs virtually lawsuits many pharmaceutical companies also named defendants female plaintiffs claim various injuries including cancerous precancerous lesions vagina cervix multiplicity pregnancy problems number suits involve infants birth defects born daughters whose mother took drug total amount claimed defendants suits amounts billion possible precisely predict outcome proceedings management 's opinion remote material liability excess amount accrued incurred company party otherwise involved environmental cleanup actions proceedings comprehensive environmental response compensation liability act commonly known superfund equivalent state laws actions proceedings seek require owners operators facilities treated stored disposed hazardous substances transporters generators substances remediate contaminated facilities andor reimburse government private parties cleanup costs company along owners operators transporters generators alleged potentially responsible party prp alleged generator hazardous substances found certain facilities proceeding government private litigants allege one prp including company jointly severally liable cleanup requirements costs although joint several liability alleged prp 's share cleanup costs frequently determined basis several factors including type quantity hazardous substances however allocation process varies greatly facility facility may take years complete company 's potential share cleanup costs also depends many prps involved action proceeding insurance coverage available indemnity contracts contribution rights prps possible predict certainty outcome action proceeding management 's opinion remote material liability excess amounts accrued incurred residents vicinity publicly owned wastewater treatment plant barceloneta puerto rico filed two lawsuits plant operator numerous companies discharge plant including subsidiary company damages injunctive relief relating odors coming plant connecting sewers one lawsuits class action claiming damages million lawsuits early stages discovery possible predict outcome company defendant approximately antitrust actions commenced starting state federal courts independent retail pharmacies chain retail pharmacies consumers plaintiffs allege price discrimination andor conspiracy company defendants restrain trade jointly refusing sell prescription drugs discounted prices plaintiffs one federal cases class action behalf approximately twothirds retail pharmacies united states alleged pricefixing conspiracy company february agreed settle federal class action total million paid full united states district court illinois approved settlement federal class action june june seventh circuit court appeals dismissed appeals settlement subject review defendants settle class action proceeded trial september trial ended november directed verdict defendants ' favor april certain plaintiffs federal class action commenced another purported class action united states district court illinois company defendants settled previous federal class action complaint alleges defendants conspired implement settlement commitments following settlement discussed district court denied plaintiffs ' motion preliminary injunction hearing company settled state retailer actions except california alabama settlement amounts material company june alabama supreme court reversed denial motion judgment thepleadings alabama retailer case court held alabama antitrust law apply conspiracies alleged interstate commerce based ruling alabama retailer case dismissed subsequently district attorney first judicial circuit filed complaint behalf alabama consumers state 's deceptive trade practices act company settled otherwise disposed state consumer cases settlement amounts material company company settled several groups similar federal antitrust cases brought food drug chain retailers independent retailer stores comprising prescription drug retail market settlement amounts material company plaintiffs antitrust actions generally seek treble damages unspecified amount injunction allegedly unlawful conduct company believes antitrust actions without merit defending vigorously march company notified united states federal trade commission ftc investigating whether company along pharmaceutical companies conspired fix prescription drug prices company believes actions lawful proper cooperating investigation however possible predict outcome investigation could result imposition fines penalties injunctive administrative remedies october company received subpoena us attorney 's office eastern district pennsylvania pursuant health insurance portability accountability act concerning company 's contracts pharmacy benefit managers pbms managed care organizations provide disease management services connection marketing pharmaceutical products appears subpoena one number addressed industry participants part inquiry among things pharmaceutical marketing practices government 's inquiry appears focus whether company 's disease management marketing programs arrangements comply federal health care laws whether value disease management programs marketing programs arrangements included calculation rebates government company cooperating investigation possible predict outcome investigation could include imposition fines penalties injunctive administrative remedies company predict whether investigation affect marketing practices sales february geneva pharmaceuticals inc geneva submitted abbreviated new drug application anda us food drug administration fda seeking market generic form claritin united states several years expiration company 's patents geneva alleged certain company 's us claritin patents invalid unenforceable claritin patents material company 's business march company filed suit federal court seeking ruling geneva 's anda submission constitutes willful infringement company 's patents challenge company 's patents without merit company believes prevail suit however litigation assurance company prevail copley pharmaceutical inc teva pharmaceuticals inc novex pharma zenith goldline pharmaceuticals individually notified company submitted anda fda seeking market certain generic forms claritin united states expiration certain company 's patents andrx pharmaceuticals llc mylan pharmaceuticals inc esi lederle inc lederle impax laboratories inc made similar submissions february alpharma uspd inc also made similar submission alleged one patents invalid unenforceable case company filed file suit federal court seeking ruling applicable anda submission proposed marketing generic product constitute willful infringement company 's patent challenge patent without merit company believes prevail suits however litigation assurance company prevail january hoffmannla roche inc filed actions company united states district court new jersey france germany alleging company 's pegintron peginterferon alfab infringes hoffmannla roche inc 's patents certain pegylated interferons company believes prevail suits however litigation assurance company prevail company responding investigations department health human services department justice certain states certain industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf united states united states district court southern district florida well investigation united states attorney 's office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp wholesale acquisition cost united states attorney 's office district massachusetts also investigating whether company 's sales product repackaged sale managed care organization included company 's medicaid best price calculations company cooperating investigations possible predict outcome investigations could include imposition fines penalties injunctive administrative remedies third quarter company 's generic subsidiary warrick pharmaceuticals sued state texas lawsuit alleges warrick supplied state false reports wholesale prices caused state pay medicaid claims prescriptions warrick 's albuterol sulfate solution higher justified level state seeks damagesof million warrick including treble damages penalties possible predict outcome litigation could result imposition fines penalties injunctive administrative remedies ftc investigating possible anticompetitive effects settlement patent lawsuits company lederle company upshersmith inc upshersmith lawsuits settled related generic versions kdur company 's longacting potassium chloride product subject abbreviated new drug applications filed lederle upshersmith investigation ongoing company believes actions lawful proper cooperating investigation however possible predict outcome investigation could result imposition fines penalties injunctive administrative remedies january jury found company 's prime pac prrs porcine respiratory reproductive syndrome vaccine infringed patent owned boehringer ingelheim vetmedica inc injunction issued august barring sales company 's vaccine company filed posttrial motions currently pending either reversal jury 's verdict new trial company believes prevail either posttrial motions appeal however litigation assurance company prevail february company stated press release fda conducting inspections company 's manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current gmps primarily relating production processes controls procedures company noted press release process control issues led reduced sales certain products us marketplace result first quarter full year sales earnings lower expected next day february lawsuit filed united states district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed others may filed plaintiffs suits filed march last day prior printing report purport represent classes shareholders purchased shares company stock july february date press release litigation early stages company believes substantial defenses intends defend suits vigorously item submission matters vote security holders applicable executive officers registrant following information regarding executive officers included herein accordance part iii item officers elected serve one year successors shall duly elected name current position business experience age richard jay kogan present position chairman board president chief executive chief executive officer officer president chief operating officer raul e cesan present position president chief executive vice president operating officer president scheringplough pharmaceuticals joseph c connors present position executive vice president senior vice president general counsel general counsel jack l wyszomierski present position executive vice president vice president treasurer chief financial officer geraldine u foster present position senior vice president investor relations andcorporate communications daniel nichols present position senior vice president taxes john p ryan present position senior vice president vice president human resources human resources scheringplough pharmaceuticals douglas j gingerella present position vice president corporate staff vice president corporate audits audits thomas h kelly present position vice president controller robert lyons present position vice president corporate information services e kevin moore present position vice president staff vice president treasurer assistant treasurer john e nine present position vice president president technical operations president schering schering laboratories technical operations joseph j larosa present position staff vice president staff vice president commercial law secretary associate senior legal director general counsel legal director part ii item market registrant 's common equity related stockholder matters common share dividends share price data approximate number holders record set forth company 's annual report shareholders incorporated herein reference item selected financial data sixyear selected financial statistical data set forth company 's annual report shareholders incorporated herein reference item management 's discussion analysis financial condition results operations management 's discussion analysis operations financial condition set forth company 's annual report shareholders incorporated herein reference item quantitative qualitative disclosures market risk market risk disclosures set forth management 's discussion analysis operations financial condition company 's annual report shareholders incorporated herein referenceitem financial statements supplementary data consolidated balance sheets december related statements consolidated income consolidated shareholders ' equity consolidated cash flows three years period ended december notes consolidated financial statements independent auditors ' report deloitte touche llp dated february quarterly data set forth company 's annual report shareholders incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information concerning directors nominees directors set forth company 's proxy statement annual meeting shareholders april incorporated herein reference information required executive officers included part filing caption executive officers registrant item executive compensation executive compensation information set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item security ownership certain beneficial owners management information concerning security ownership certain beneficial owners management set forth company 's proxy statement annual meeting shareholders april incorporated herein reference item certain relationships related transactions information concerning certain relationships related transactions set forth company 's proxy statement annual meeting shareholders april incorporated herein reference part iv item exhibits financial statement schedules reports form k financial statements following consolidated financial statements independent auditors ' report included company 's annual report shareholders incorporated herein reference statements consolidated income years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders ' equity years ended december notes consolidated financial statements independent auditors ' reporta financial statement schedules independent auditors ' report schedule ii valuation qualifying accounts schedules included omitted applicable required required information set forth financial statements notes thereto columns omitted schedules filed omitted information applicable financial statements fifty percent less owned companies accounted equity method omitted considered individually aggregate constitute significant subsidiary exhibits exhibit number description complete copy certificate incorporation amended currently effect incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended june form q certificate amendment certificate incorporation incorporated reference exhibit company 's quarterly report period ended march form q file b complete copy bylaws amended currently effect incorporated reference exhibit company 's registration statement form file amendment bylaws effective september incorporated reference exhibit company 's quarterly report period ended september form q file rights agreement company bank new york dated june incorporated reference exhibit form filed company june file b indenture dated november company chase manhattan bank na trustee incorporated reference exhibit company 's registration statement form file c form participation rights agreement company chase manhattan bank national association trustee incorporated reference exhibit company 's registration statement form amendment file company 's executive incentive plan amended trust related thereto plan incorporated reference exhibit company 's quarterly report period ended march form q executive incentive plan amended restated october filed document file ii trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust filed document file b company 's stock incentive plan amended incorporated reference exhibit company 's annual report form k file c company 's stock incentive plan amended incorporated reference exhibit company 's annual report form k file amendment december incorporated reference exhibit company 's annual report form k file company 's stock incentive plan incorporated reference exhibit company 's quarterly report period ended september form q amendment stock incentive plan incorporated reference exhibit company 's quarterly report period ended march form q file e employment agreement company richard jay kogan amended incorporated reference exhibit eii company 's annual report first amendment incorporated reference exhibit b company 's quarterly report period ended june form q second amendment incorporated reference exhibit eii company 's annual report form k third amendment incorporated reference exhibit company 's quarterly report period ended september form q fourth amendment incorporated reference exhibit b company 's quarterly report period ended march form q fifth amendment incorporated reference exhibit eii company 's annual report file e ii form employment agreement company executive officers effective upon change control incorporated reference exhibit eiv company 's annual report form amendment incorporated reference exhibit company 's quarterly report period ended september form q file e iii employment agreement company raul e cesan incorporated reference exhibit evi company 's annual report file e iv employment agreement company robert p luciano amended incorporated reference exhibit ei company 's annual report first amendment incorporated reference exhibit company 's quarterly report period ended june form q second amendment incorporated reference ei company 's annual report third amendment incorporated reference exhibit company 's quarterly report period ended march form q file ev agreement company robert p luciano incorporated reference exhibit company 's quarterly report period ended march form q file f amended restated directors deferred compensation plan trust related thereto incorporated reference exhibit b company 's quarterly report period ended september form q trust agreement incorporated reference exhibit company 's annual report amendment trust agreement incorporated reference exhibit b company 's quarterly report period ended march form q amended restated defined contribution trust filed document exhibit ii file g supplemental executive retirement plan trust related thereto incorporated reference exhibit e company 's quarterly report period ended march form q amendment incorporated reference exhibit company 's quarterly report period ended september form q second amendment supplemental executive retirement plan effective october filed document amended restated trust agreement incorporated reference exhibit g company 's annual report form k file h amended restated directors ' stock award plan incorporated reference exhibit c company 's quarterly report period ended september form q file deferred compensation plan incorporated reference exhibit b company 's quarterly report period ended september form q deferred compensation plan amended restated october filed document file j amended restated directors deferred stock equivalency program incorporated reference exhibit company 's quarterly report period ended september form q file k company 's form split dollar agreement related collateral assignment company executive officers incorporated reference exhibit l company 's annual report form k amendments incorporated reference exhibit g company 's quarterly report period ended march formq file l company 's retirement benefits equalization plan second amendment effective october filed document incorporated reference exhibit f company 's quarterly report period ended march form q amendment incorporated reference exhibit b company 's quarterly report period ended september form q file computation ratio earnings fixed charges filed document financial section company 's annual report shareholders exception portions said annual report specifically incorporated reference filed document report shall deemed filed part subsidiaries registrant filed document consents experts counsel filed document power attorney filed document compensatory plan contract arrangement